HS
VRNA

HighVista Strategies’s Verona Pharma VRNA Stock Holding History

HighVista Strategies’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28,880
Closed -$2.73M – 174
2025
Q2 		$2.73M Buy
28,880
+12,179
+73% +$902K 1% 23
2025
Q1 		$1.06M Sell
16,701
-7,038
-30% -$421K 0.41% 106
2024
Q4 		$1.1M Hold
23,739
– – 0.41% 105
2024
Q3 		$683K Sell
23,739
-8,710
-27% -$214K 0.24% 108
2024
Q2 		$469K Hold
32,449
– – 0.17% 117
2024
Q1 		$522K Hold
32,449
– – 0.19% 116
2023
Q4 		$645K Buy
32,449
+2,576
+9% +$38K 0.23% 109
2023
Q3 		$487K Sell
29,873
-4,154
-12% -$80K 0.23% 111
2023
Q2 		$719K Sell
34,027
-13,696
-29% -$292K 0.33% 83
2023
Q1 		$958K Sell
47,723
-20,968
-31% -$453K 0.78% 37
2022
Q4 		$1.79M Buy
+68,691
New +$915K 1.07% 30
2021
Q2 		– Sell
-36,638
Closed -$306K – 147
2021
Q1 		$306K Buy
36,638
+9,957
+37% +$82.6K 0.23% 77
2020
Q4 		$187K Buy
+26,681
New +$180K 0.12% 72

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HighVista Strategies's VRNA Position: Q3 2025 in Review

HighVista Strategies sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 28,880 shares — an estimated $2.73M sold.

HighVista Strategies first reported a position in VRNA in Q4 2020 and held it in 13 quarters. The position peaked at $2.73M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • HighVista Strategies reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • HighVista Strategies sold 28,880 Verona Pharma shares in Q3 2025, an estimated $2.73M.
  • HighVista Strategies first reported a position in Verona Pharma in Q4 2020 and held it in 13 quarters.
  • HighVista Strategies's Verona Pharma position peaked at $2.73M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on HighVista Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.